The current study proves, for the first time, that the administration of MWEs prevents CCl4-induced liver damage in a dose-dependent manner. MWEs clearly reduced the CCl4-induced TBARS
formation and the serum AST, ALT, and ALP levels. Reduced lipid
deposition and liver fibrosis were also observed in the groups
cotreated with MWE but not in the groups treated with CCl4alone.
In addition, MWEs reduced the expression of CCl4-elicited proinflammatory genes such as iNOS, COX 2, and NFjB. These results
indicate that MWEs exhibit hepatoprotective effects via their antioxidant and anti-inflammation properties. In addition, MWEs such
as silymarin are potential liver protective and curative agents